(a) Positron emission tomography (PET) enables high-sensitivity and quantitative imaging of whole-body tracer distribution. PET tracer principle and the development of agents that fluorescently-convert the Cerenkov radiation optical decay signal. This technique can be applied to monitor other markers and facilitates a shift towards activatable nuclear medicine agents.Ĭonventional PET and Cerenkov Luminescence In addition to information from a PET scan, we demonstrate novel medical utility by quantitatively determining prognostically relevant enzymatic activity. This approach reduces background signal compared to conventional fluorescence imaging. Disease markers were detected using nanoparticles to produce secondary Cerenkov-induced fluorescence. This was accomplished utilizing Cerenkov luminescence (CL), the light produced by β-emitting radionuclides such as clinical positron emission tomography (PET) tracers. Here we introduce a framework of novel targeted and activatable probes excited by a nuclear decay-derived signal to identify and measure molecular signatures of disease. Sensitive imaging of gamma rays is widely used, but radioactive decay is a physical constant and signal is independent of biological interactions.
In the era of personalized medicine there is an urgent need for in vivo techniques able to sensitively detect and quantify molecular activities.
0 kommentar(er)
